Titan has a diverse and relatively advanced portfolio. Its most important drugs are licensed to others, so Titan is a somewhat passive player. The TTP pipeline includes:
1. Iloperidone - licensed to Vanda Pharmaceuticals, which has submitted an NDA to the FDA. It appears to have a strong chance of approval in 2008, it serves large market (schizophrenia), is something of a "me-too" drug.
2. Spheramine: licensed to Bayer-Schering, which is wrapping up a second phase II trial for Parkinsons disease. Anecdotal evidence suggests that it is quite effective, but it involves a brain implant, which is pretty scary. It will take a lot of time for the phase III to take place, and there are competitive treatments emerging.
3. DIPTA for hyperlipidemia: good research partner in Johns Hopkins, which is undertaking a Phase II study.
4. Probuphine: This is a delivery method for a drug to treat heroin addicts. It has many important advantages, but the patents are about to expire. This is now in a phase III trial, but it is a relatively small one and does not appear to be a pivotal trial.
5. Gallium Maltolate: Phase I not begun.